Crossmark

98 ATA3271: an armored, next-generation off-the-shelf, allogeneic, mesothelin-CAR T cell therapy for solid tumors

Crossref DOI link: https://doi.org/10.1136/jitc-2020-SITC2020.0098

Published Online: 2020-12-10

Published Print: 2020-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Liu, Jiangyue

Chen, Xianhui

Karlen, Jason

Brito, Alfonso

Jheng, Tiffany

Foubert, Philippe

Krishnamurthy, Janani

Bulliard, Yannick

Aftab, Blake
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct03394365 at ClinicalTrials.gov

Documents that mention this clinical trial

136 ATA3271: An armored, next-generation off-the-shelf, allogeneic, mesothelin-CAR T cell therapy for solid tumors
https://doi.org/10.1136/jitc-2021-sitc2021.136

98 ATA3271: an armored, next-generation off-the-shelf, allogeneic, mesothelin-CAR T cell therapy for solid tumors
https://doi.org/10.1136/jitc-2020-sitc2020.0098
License Information

License valid from 2020-12-09